{
}
Regenxbio Inc showcased its leadership in gene therapy at the UBS Virtual CNS Day 2025, highlighting three late-stage programs: RGX-121, RGX-202, and RGX-314. The company has completed the BLA submission for RGX-121, with potential approval by the end of 2025, while RGX-202 aims for accelerated approval with pivotal enrollment expected to finish in the latter half of the year. Additionally, RGX-314's partnership with AbbVie could yield $500 million in milestone payments, focusing on diabetic retinopathy and wet AMD.
REGENXBIO is optimistic about achieving accelerated approval for its gene therapy targeting micro dystrophin, particularly in younger patients where existing treatments are lacking. The company emphasizes the importance of safety and differentiation, noting their approach to mitigate complement activation risks and the promising functional data observed in clinical trials. Ongoing discussions with the FDA have reinforced their confidence in the approval pathway, with plans to enroll approximately 30 patients by the end of the year.
Light Horse Therapeutics has secured $62 million in Series A financing and formed a partnership with Novartis, which includes a $25 million upfront payment and potential milestone payments of up to $1 billion. The biotech aims to revolutionize drug discovery with its genetic editing-based platform, initially focusing on challenging oncology targets while exploring other therapeutic areas in the future.
Light Horse Therapeutics has launched with $62 million in Series A financing led by Versant Ventures, alongside partners including Novartis. The company focuses on developing small molecule therapeutics using a precision gene editing platform to tackle challenging oncology targets, with potential for broader applications. The collaboration with Novartis includes a $25 million upfront payment and up to $1 billion in milestone payments, aiming to create first-in-class therapies.
Light Horse Therapeutics has launched with a $62-million series A financing and a collaboration with Novartis potentially worth over $1 billion. The San Diego-based biotech employs a "function-first" approach to drug discovery, focusing initially on oncology targets while integrating precision genome editing techniques. The partnership includes a $25-million upfront payment and opportunities for significant R&D and sales milestones.
Versant Ventures has launched a new biotech company, Light Horse, securing $62 million in a Series A funding round backed by Bristol Myers Squibb, AbbVie, and others. The company also announced a partnership with Novartis, marking a significant step in its development.
Roche is projected to lead the pharmaceutical industry in sales by 2025, despite not having any products in the top drug rankings. Eli Lilly and Novo Nordisk are expected to rise in the rankings, with combined sales from their GLP-1 drugs surpassing $70 billion this year. Meanwhile, Pfizer is anticipated to drop from fifth to ninth place, while Merck & Co. and AbbVie are expected to secure the second and third spots, respectively.
As 2024 closes with the S&P 500 achieving a 25% return, investors are advised to consider defensive strategies amid potential market volatility. AbbVie, with a strong dividend yield and promising drug sales growth, and Pfizer, offering a high yield and new growth drivers, are highlighted as solid healthcare sector investments for uncertain times. Both companies are well-positioned for continued success as they enter 2025.
The Global Uveitis Treatment market is projected to grow from USD 725 million in 2024 to USD 1.28 billion by 2032, with a CAGR of 8.5%. The study covers various treatment types, including corticosteroids and biologic agents, and offers customization options for regional and application-specific analysis. Key players include Novartis, Pfizer, and AbbVie, with North America leading the market and Asia-Pacific identified as the fastest-growing region.
AbbVie has acquired Nimble Therapeutics for $200 million, gaining access to an oral peptide drug candidate aimed at treating psoriasis by inhibiting the IL23 receptor. This addition complements AbbVie's existing injectable drug, Skyrizi, and aims to address significant unmet medical needs in autoimmune diseases.
ABBVIE
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Regenxbio showcases gene therapy advancements at UBS Virtual CNS Day 2025
13:13 18.03.2025
advancements in gene therapy for muscular dystrophy show promising clinical results
13:12 18.03.2025
light horse therapeutics secures 62 million and partners with novartis
United States Dollar
Bristol-Myers Squibb Co
Novartis AG
ABBVIE
ARE
USA
John Tallarico
Markus Renschler
Show more
13:38 10.01.2025
light horse therapeutics launched with 62 million funding and novartis partnership
United States Dollar
Bristol-Myers Squibb Co
Novartis AG
ABBVIE
ARE
JPN
USA
Ben Cravatt
Brian Liau
Markus Renschler
John Tallarico
Nathanael Gray
Show more
13:38 10.01.2025
light horse therapeutics secures funding and partnership with novartis
United States Dollar
Bristol-Myers Squibb Co
Novartis AG
ABBVIE
USA
Ben Cravatt
Laure Escoubet
Brian Liau
Markus Renschler
John Tallarico
Nathanael Gray
Show more
16:13 09.01.2025
Versant launches Light Horse with 62 million funding and Novartis partnership
15:32 09.01.2025
roche set to lead global pharma sales in 2025 as rivals rise
United States Dollar
Merck & Co., Inc.
Regeneron Pharmaceuticals, Inc.
Hoffmann-La Roche AG
ABBVIE
Pfizer Inc.
Novartis AG
Sanofi
AstraZeneca PLC
Gilead Sciences, Inc.
GSK plc
Eli Lilly and Co
Johnson & Johnson
Novo Nordisk A/S
Robert F. Kennedy Jr.
Show more
19:07 03.01.2025
two healthcare dividend stocks to consider during market volatility
12:50 22.12.2024
global uveitis treatment market poised for significant growth by 2032
Pfizer Inc.
Bayer AG
Novartis AG
Regeneron Pharmaceuticals, Inc.
Merck & Co., Inc.
CIPLA LTD
Lupin Limited
Hoffmann-La Roche AG
Bausch Health Companies Inc.
BIOGEN
ABBVIE
Alimera Sciences Inc.
SAU
ISR
FRA
RUS
DEU
TWN
ARG
ARE
AUT
TUR
SGP
NZL
CHL
USA
BRA
CAN
ITA
JPN
IDN
GBR
ESP
IND
MYS
COL
AUS
THA
EGY
VNM
KOR
PHL
CHN
ZAF
MEX
Nidhi Bhavsar
Show more
20:41 19.12.2024
abbvie acquires nimble therapeutics to enhance autoimmune disease treatment options
16:27 17.12.2024
Trending
Subcategory
Corporate News
Industry Trends
Stock Market Updates
Industry Mergers & Acquisitions
Banking Regulations
Workplace Trends
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
CEO Changes
Market Analysis and Predictions
Central Bank Actions
Startups & Entrepreneurship
Global Trade Developments
Government Policies
Financial Scams and Security
Domestic Politics
Private Equity Deals
Government Economic Policies
Supply Chain Management
Countries:
Companies:
JPMorgan Chase & Co.
Tesla, Inc.
Barclays PLC
Credit Suisse Lux Digital Healt
Bank of America Corporation
UniCredit S.p.A.
Deutsche Bank Money Market PP
The Goldman Sachs Group, Inc.
UBS Group AG
Banco BPM S.p.A.
Apple Inc.
BNP Paribas SA
Wells Fargo & Company
Commerzbank AG
Banco Santander, S.A.
CREDIT AGRICOLE
Lloyds Banking Group plc
SpaceXCoin USD
Morgan Stanley
Credit Suisse Strategic Income I
Currencies:
United States Dollar
Euro
British Pound Sterling
Swiss Franc
Chinese Yuan
Indian Rupee
Japanese Yen
South Korean Won
Danish Krone
Hong Kong Dollar
Australian Dollar
Singapore Dollar
Offshore Chinese Yuan
Mexican Peso
Russian Ruble
Chilean Peso
Canadian Dollar
United Arab Emirates Dirham
Norwegian Krone
Swedish Krona
People: